ISSN: 2332-0877

感染症と治療ジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Broad Humoral Immunity Generated in Mice by a Formulation Composed by Two Antigens from Delta Variant of SARS-CoV-2

Yadira Lobaina, Rong Chen, Edith Suzarte, Panchao Ai, Vivian Huerta, Changyuan Tan, Liz Alvarez-Lajonchere, Yang Liling, Alexis Musacchio, Ricardo Silva, Gerardo Guillén, Jiang Zaixue, Ke Yang, Yasser Perera, Lisset Hermida

Study background: Due to the rapid development of new variants of SARS-CoV-2 virus, as well as the real threat of new Coronavirus zoonosis events, the development of a preventive vaccine with a broader scope of functionality is highly desirable. Previously, we reported the functionality of a nasal formulation based on the preparation of the nucleocapsid protein with the ODN-39M and combined with RBD, both antigens from Delta variant of SARS-CoV-2. This combination induces a cross reactive immunity in mucosal and systemic compartments until sarbecovirus level. In the present study, we explored the magnitude of the immunity generated in Balb/C mice by the same formulation, but adding alum as adjuvant, so as to enhance the humoral immunity against the two antigens.

Methods: Animals were immunized with three doses of the bivalent formulation, administered by subcutaneous route. The humoral immunity was tested by ELISA and by a surrogate of viral neutralization test. The cell mediated immunity was also explored.

Results: High levels of antibodies against both antigens (N and RBD) were obtained upon immunization. Additionally, the anti-RBD Abs with neutralizing capacity reacted against the three SARS-CoV-2 variants of RBD assayed, including omicron. At the same time, the Abs also recognized the nucleocapsid proteins from: SARSCoV- 1 and SARS-CoV-2 delta and omicron.

Conclusion: Taken together, these results make the bivalent formulation tested, an attractive component of a pan Corona vaccine able to broaden the scope of humoral immunity against both antigens. This will be particularly important in the reinforcement of immunity from previously vaccinated and/or infected populations.